Kenan Turnacioglu
Président chez Paige.Ai, Inc.
Profil
Kenan Turnacioglu is the founder of PointState Capital LP, which was founded in 2011.
He held the title of Vice Chairman at PointState Capital LP.
He is currently the Chairman at Paige.
Ai, Inc. since 2017.
Dr. Turnacioglu has also held former positions as a Director at Stemcentrx, Inc. from 2013 to 2016, as well as a Director at Agensys, Inc. from 2004 to 2007.
He was also a Director at Immunai, Inc., HealthCor Catalio Acquisition Corp., and Nyu Langone Cancer Center from 2010 to 2015.
Additionally, Dr. Turnacioglu worked as an Equity Analyst at Duquesne Capital Management LLC.
He was a General Partner at Catalio Capital Management LP from 2020 to 2021.
Dr. Turnacioglu obtained a doctorate degree from the University of Pennsylvania and an undergraduate degree from Rutgers State University of New Jersey.
Postes actifs de Kenan Turnacioglu
| Sociétés | Poste | Début |
|---|---|---|
Paige.Ai, Inc.
 Paige.Ai, Inc. Miscellaneous Commercial ServicesCommercial Services Paige Ai, Inc. engages in revolutionizing pathology and strengthen lynchpin of medical diagnostics with quantitative, computational technology, fusing machine learning, and human expertise. It involves in building an artificial intelligence to change clinical diagnosis and treatment of cancer. The company is headquartered in New York, NY. | Président | 01/01/2017 |
Anciens postes connus de Kenan Turnacioglu
| Sociétés | Poste | Fin |
|---|---|---|
Catalio Capital Management LP
 Catalio Capital Management LP Investment ManagersFinance Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York. | Membre du Comité d'Investissement | 31/10/2021 |
Stemcentrx, Inc.
 Stemcentrx, Inc. BiotechnologyHealth Technology Stemcentrx, Inc. develops life-changing therapies for cancer patients. It develops proprietary discovery platforms that yield unprecedented insight into the biology of tumors and are being exploited to develop potent new cancer drugs. The firm specializes in designing drugs to target cancer stem cells, which are the cells that cause cancer to spread throughout the body. The company was founded by Brian Christopher Slingerland, Daniel T. Reiner and Scott J. Dylla in 2008 and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | 01/01/2016 |
| Nyu Langone Cancer Center | Directeur/Membre du Conseil | 01/01/2015 |
Duquesne Capital Management LLC
 Duquesne Capital Management LLC Investment ManagersFinance Founded in 1981 by Stanley Druckenmiller, Duquesne Capital Management LLC is a hedge fund manager located in Pittsburgh, Pennsylvania with an additional office in New York City | Analyst-Equity | 31/10/2010 |
Agensys, Inc.
 Agensys, Inc. Miscellaneous Commercial ServicesCommercial Services Agensys, Inc. develops a pipeline of therapeutic fully human monoclonal atibodies (mAbs) to treat cancer. It develops a pipeline of naked and antibody-drug conjugated (ADC) therapeutic antibodies to treat cancer indications, including prostate, kidney, pancreas, ovary, bladder, lung, colon, breast, and skin. The company was founded in 1997 and is headquartered in Santa Monica, CA. | Directeur/Membre du Conseil | 01/01/2007 |
Formation de Kenan Turnacioglu
| University of Pennsylvania | Doctorate Degree |
| Rutgers State University of New Jersey | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Duquesne Capital Management LLC
Duquesne Capital Management LLC Investment ManagersFinance Founded in 1981 by Stanley Druckenmiller, Duquesne Capital Management LLC is a hedge fund manager located in Pittsburgh, Pennsylvania with an additional office in New York City | Finance |
Agensys, Inc.
Agensys, Inc. Miscellaneous Commercial ServicesCommercial Services Agensys, Inc. develops a pipeline of therapeutic fully human monoclonal atibodies (mAbs) to treat cancer. It develops a pipeline of naked and antibody-drug conjugated (ADC) therapeutic antibodies to treat cancer indications, including prostate, kidney, pancreas, ovary, bladder, lung, colon, breast, and skin. The company was founded in 1997 and is headquartered in Santa Monica, CA. | Commercial Services |
PointState Capital LP
 PointState Capital LP Investment ManagersFinance PointState Capital LP is an independent, SEC-registered investment manager and hedge fund manager headquartered in New York City. The firm was founded in 2011 by Joshua Samuelson and Zachary Schreiber. PointState Capital provides discretionary investment advisory services, which include but not limited to, managing and directing the investment and reinvestment of assets for private investment funds and has provided these services to a discretionary separately managed account. Investors in the PointState Funds primarily consist of charitable foundations, institutions, endowments, funds of funds, private or family-owned investment entities, trusts and high net-worth individuals. | Finance |
Catalio Capital Management LP
Catalio Capital Management LP Investment ManagersFinance Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York. | Finance |
Paige.Ai, Inc.
Paige.Ai, Inc. Miscellaneous Commercial ServicesCommercial Services Paige Ai, Inc. engages in revolutionizing pathology and strengthen lynchpin of medical diagnostics with quantitative, computational technology, fusing machine learning, and human expertise. It involves in building an artificial intelligence to change clinical diagnosis and treatment of cancer. The company is headquartered in New York, NY. | Commercial Services |
HealthCor Catalio Acquisition Corp.
 HealthCor Catalio Acquisition Corp. Financial ConglomeratesFinance HealthCor Catalio Acquisition Corp. operates as a Cayman Islands exempted company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The company was founded on November 18, 2020 and is headquartered in New York, NY. | Finance |
Stemcentrx, Inc.
Stemcentrx, Inc. BiotechnologyHealth Technology Stemcentrx, Inc. develops life-changing therapies for cancer patients. It develops proprietary discovery platforms that yield unprecedented insight into the biology of tumors and are being exploited to develop potent new cancer drugs. The firm specializes in designing drugs to target cancer stem cells, which are the cells that cause cancer to spread throughout the body. The company was founded by Brian Christopher Slingerland, Daniel T. Reiner and Scott J. Dylla in 2008 and is headquartered in San Francisco, CA. | Health Technology |
| Nyu Langone Cancer Center | |
Immunai, Inc.
 Immunai, Inc. Packaged SoftwareTechnology Services Immunai, Inc. engages in decoding of immune system to improve health. It offers an immune profiling platform, which is used to advance research and development in checkpoint blockade, cancer cell therapy, and cancer vaccines. The company was founded by Noam Solomon, Luis Voloch, Danny Wells, Ansuman Satpathy and Dan R. Littman in December 2018 and is headquartered in New York, NY. | Technology Services |